A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis
← catalyst calendarNCT06752850 · readout in 90 d
Sponsored by Swedish Orphan Biovitrum (industry) · SOBI.ST — their whole pipeline →. With PSI CRO.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
37actual
Sites
10
Countries
Italy, Norway, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-19 | actual | When the study began enrolling |
| Primary completion | 2026-11-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-28 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Haemophilia A (Moderate or Severe)
- Hemophilia, Classic
- Haemophilia
- Hemophilia
- Classic Hemophilia
- Synovial Hypertrophy
Intervention
- Drug: Efanesoctocog alfa
Primary outcome
what the primary-completion date above is the date OFHaemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovial hypertrophy domain score decrease.
measured Baseline to 12 months
Permalink · SOBI.ST's whole pipeline · Catalyst calendar · Every registered study · What changed